CD274 and breast cancer: Several monoclonal antibodies targeting ICR markers, including cytotoxic T lymphocyte-associated antigen (CTLA-4), programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1), have shown good clinical activity in BC [127,128,129,130].